Oncology biotech Mersana Therapeutics has expanded its relationship with Takeda, forging an agreement to develop targeted cancer drugs with as much as $300 million on the line.
Now, more than ever, the life sciences industry is all about innovative and disruptive technologies. Every year for the past decade, FierceBiotech has made its picks on which companies hold the best odds for success in our Fierce 15 report. This year, though, we've added another Fierce 15 to focus on medical devices and diagnostics. I'd like to encourage readers to consider the differences by comparing the companies in each report.
Nick Leschly, the CEO of Bluebird Bio, playfully dubbed the ambitious spirit of biotechs Levin Syndrome, a fictional affliction named after Third Rock Ventures' Mark Levin that compels biotech entrepreneurs to, as they say, go big or go home. Our Fierce 15 companies are all "going big." They also went home… with trophies. Check out the slideshow below.
There's more than one way to build a biotech company. And this year's Fierce 15 companies reflect a range of companies operating with a spectrum of business models. Here's the full report >> Click here to view a video of FierceBiotech Editor John Carroll announcing the Fierce 15 at BioPharm America >>
Biotech startups Adimab and Mersana Therapeutics have formed an alliance to provide pharma companies one-stop shopping for coveted antibody-drug conjugates (ADCs). The unique partnership enables drugmakers to tap Adimab's discovery engine for antibodies tailored to fit with Mersana's next-generation tech that links the biologics and, say, small-molecule drugs to its proprietary polymer.
Fresh from revealing a $2.6 billion fund last week, New Enterprise Associates (NEA) has jumped aboard as a lead backer of Mersana Therapeutics' next-gen antibody drug conjugates--one of the hottest areas of cancer treatment.
Endo Pharmaceuticals ($ENDP) has tapped Mersana to create antibody-drug conjugates against an undisclosed cancer target.
Cambridge, MA-based Mersana Therapeutics has forged its first big licensing pact, inking a $334 million collaboration deal with Teva for a preclinical cancer drug program. Under the deal, Mersana